Abstract:10544 Background: Screening the biomarkers from the cell-free DNA (cfDNA) of peripheral blood is a non-invasive and promising method for cancer diagnosis. Among diverse types of biomarkers, epigenetic biomarkers have been reported to be one of the most promising ones. Epigenetic modifications are widespread on the human genome and generally have strong signals due to the similar methylation patterns shared by adjacent CpG sites. Although some epigenetic diagnostic methods have been developed based on cfDNAs, few of them could be applied to pan-cancer and their sensitivities are barely satisfactory for early cancer detection. Methods: Targeted methylation sequencing was performed using our in-house-designed panel targeting regions with abundant cancer-specific methylation CpGs. The cfDNA samples from 80 healthy individuals and 549 cancer patients of 14 cancer types were separately sequenced. The dataset was randomly split into one discovery dataset and one validation dataset. Moreover, cfDNA samples from four cancer patients were diluted with the healthy cfDNAs to generate 12 in vitro simulated samples with low circulating tumor DNA (ctDNA) fraction. Additionally, DNAs extracted from 130 unmatched tumor formalin fixation and paraffin embedding (FFPE) samples of 10 cancer types were sequenced to screen the diagnostic biomarkers. Adjacent CpG sites were first merged into methylation-correlated blocks (MCB) according to their correlations of methylation levels in tumor DNAs. The MCBs with higher methylation levels in tumor DNAs than that of healthy cfDNAs (from the discovery dataset) were defined as our hypermethylation biomarkers. For each cfDNA sample, a hypermethylation score (HM-score) was computed to measure the overall methylation level difference of selected biomarkers. The performance of our method was evaluated with the real-world dataset, while the limit of detection was estimated using the simulated low-ctDNA samples. Results: Our model based on 37 hypermethylation MCB biomarkers achieved an area under the curve (AUC) of 0.89 and 0.86 in the real-world pan-cancer discovery and validation cfDNA datasets, respectively. Furthermore, the overall specificity and sensitivity are 100% and 76.19% in the discovery dataset, and 96.67% and 72.86% in the validation dataset. In the validation dataset, 28/40 (70%) of early-stage colorectal cancer patients and 10/20 (50%) of non-small-cell lung cancer patients were successfully diagnosed. Additionally, all the simulated samples with theoretical ctDNA factions over 0.5% were predicted as diseased, demonstrating the ability of our method to detect tumor signals at early stages. Conclusions: Our cfDNA-based epigenetic method outperforms currently available methods in various cancer types, and is promising to be applied to early-stage cancer detection and samples with low ctDNA fractions.

A multiplex blood-based assay targeting DNA methylation in PBMCs enables early detection of breast cancer

B-381 A Multiplex Blood-based Assay Targeting DNA methylation in Peripheral Blood Mononuclear Cells Enables Early Detection of Breast Cancer

Genome-wide cell-free DNA methylation analyses improve accuracy of non-invasive diagnostic imaging for early-stage breast cancer

Microarray-based analysis of whole-genome DNA methylation profiling in early detection of breast cancer.

DNA Methylation Profiles and Their Diagnostic Utility in BC

Circulating cell-free DNA-based methylation patterns for breast cancer diagnosis

A multiplex methylation-specific PCR assay for the detection of early-stage ovarian cancer using cell-free serum DNA.

B-382 Accurate and Early Detection of Colorectal Cancer Using a Multilocus DNA Methylation Markers-based Testing in Peripheral Blood Mononuclear Cells

DNA methylation-based testing in peripheral blood mononuclear cells enables accurate and early detection of colorectal cancer

A Multiplex Methylation-Specific Pcr Assay For Detection Of Early-Stage Ovarian Cancer Using Cell-Free Serum Dna

Prediction of blood-based biomarkers and subsequent design of bisulfite PCR-LDR-qPCR assay for breast cancer detection

Methylation profiling of 48 candidate genes in tumor and matched normal tissues from breast cancer patients

A urine-based DNA methylation assay to facilitate early detection and risk stratification of bladder cancer

DNA methylation signatures provide novel diagnostic biomarkers and predict responses of immune therapy for breast cancer

Detection of aberrant methylation of a six-gene panel in serum DNA for diagnosis of breast cancer

A DNA Methylation-Based Panel for the Prognosis and Diagnosis of Patients With Breast Cancer and Its Mechanisms

Hypermethylation of Tumor Suppressor Genes Involved in Critical Regulatory Pathways for Developing A Blood-Based Test in Breast Cancer

An Ultrasensitive Method for Noninvasive Pan-Cancer Early Detection Based on Targeted Methylation Sequencing of Cell-Free DNA.

Integrative analysis of DNA methylation and gene expression profiles identified potential breast cancer-specific diagnostic markers

Whole‐genome circulating tumor DNA methylation landscape reveals sensitive biomarkers of breast cancer

DNA Methylation Markers for Breast Cancer Detection in the Developing World